Perrigo (PRGO) Lags Q2 Earnings and Revenue Estimates

Perrigo (PRGO) reported Q2 earnings of $0.57 per share, missing the Zacks Consensus Estimate of $0.59, and revenues of $1.06 billion, which missed consensus by 2.63%. This extends a trend where the company has not beaten revenue estimates in the last four quarters. Despite the quarterly miss, Perrigo's stock maintains a Zacks Rank #2 (Buy), indicating an expectation for near-term market outperformance, though the sustainability of price movement will largely hinge on management's upcoming earnings call commentary.

Analysis

Perrigo (PRGO) delivered a mixed Q2 2025 report, missing consensus estimates on both revenue and earnings while showing modest year-over-year profit growth. The company reported quarterly earnings of $0.57 per share, a 3.39% miss against the Zacks Consensus Estimate of $0.59, though this figure represents an increase from $0.53 per share in the prior-year period. On the top line, revenues of $1.06 billion fell short of estimates by 2.63% and were slightly down from $1.07 billion a year ago. This marks the fourth consecutive quarter that Perrigo has failed to surpass revenue estimates, indicating a persistent challenge in meeting market expectations. The stock's year-to-date performance, a 3.5% gain, already reflects this struggle as it significantly trails the S&P 500's 7.1% advance. A key point of contention for investors is the conflicting signals between these results and the stock's pre-earnings Zacks Rank #2 (Buy), which was based on a favorable trend in estimate revisions. The sustainability of this bullish rating is now in question and will be heavily dependent on management's forward-looking commentary. Compounding the challenge is the stock's operating environment, as the broader Medical - Products industry currently ranks in the bottom 41% of Zacks industries, suggesting sector-wide headwinds.

Key Decisions for Investors

• Investors should closely scrutinize management's commentary on the upcoming earnings call for a clear explanation of the revenue shortfall and for any revisions to future guidance.
• Monitor analyst earnings estimate revisions over the coming days, as a negative shift would invalidate the current Zacks #2 (Buy) rating and signal potential further downside for the stock.
• Given the consistent revenue misses and weak industry backdrop, a cautious approach is warranted until there is tangible evidence that the company can reverse its top-line stagnation and meet its forward-looking targets.
• Consider the stock's ongoing underperformance against the S&P 500 as a key risk factor, weighing whether the potential for a turnaround justifies holding a position in a lagging company within a poorly ranked industry.